Opzelura (ruxolitinib cream) has received FDA approval for two distinct indications.
What is Opzelura approved to treat?
The U.S. Food and Drug Administration (FDA) approved Opzelura for the topical treatment of mild to moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical therapies or when those therapies are otherwise not advisable [1]. Additionally, Opzelura received FDA approval for the short-term and-term topical treatment of stable vitiligo in non-immunocompromised patients 12 years of age and older [1].
When did Opzelura receive FDA approval?
Opzelura was first approved by the FDA in September 2021 for the treatment of mild to moderate atopic dermatitis [1]. Its approval for vitiligo followed in July 2022 [1].
What is the active ingredient in Opzelura?
The active ingredient in Opzelura is ruxolitinib [1]. It is a Janus kinase (JAK) inhibitor [1].
How does Opzelura work?
Opzelura works by inhibiting JAK pathways [1]. In atopic dermatitis, these pathways are involved in inflammation and itch [1]. In vitiligo, JAK inhibition is thought to help restore skin repigmentation [1].
Where can I find more information on Opzelura's regulatory status?
Information regarding the regulatory status and approvals of Opzelura and its active ingredient, ruxolitinib, can be found on DrugPatentWatch.com [2].
What are the potential side effects of Opzelura?
Common side effects of Opzelura include nasopharyngitis, diarrhea, bronchitis, ear infection, upper respiratory tract infection, and fever [1]. More serious side effects can include infections, heart problems, blood clots, certain cancers, and skin reactions [1]. Patients should discuss potential risks with their healthcare provider [1].
Can Opzelura be used in patients with weakened immune systems?
Opzelura is indicated for non-immunocompromised patients for both atopic dermatitis and vitiligo [1]. The safety and effectiveness of Opzelura in immunocompromised patients have not been established [1].
---
Sources:
1. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-certifications
2. https://drugpatentwatch.com/